Allworth Financial LP Acquires 216 Shares of Hologic, Inc. (NASDAQ:HOLX)

Allworth Financial LP raised its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 46.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 686 shares of the medical equipment provider’s stock after purchasing an additional 216 shares during the quarter. Allworth Financial LP’s holdings in Hologic were worth $40,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. EverSource Wealth Advisors LLC raised its position in shares of Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 260 shares in the last quarter. Raiffeisen Bank International AG bought a new stake in Hologic during the fourth quarter worth approximately $49,000. West Financial Advisors LLC purchased a new stake in Hologic during the first quarter valued at approximately $50,000. Covestor Ltd raised its position in Hologic by 49.3% during the fourth quarter. Covestor Ltd now owns 1,033 shares of the medical equipment provider’s stock valued at $75,000 after purchasing an additional 341 shares during the period. Finally, Transce3nd LLC bought a new stake in shares of Hologic in the 4th quarter valued at approximately $96,000. Institutional investors own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on HOLX shares. Royal Bank Of Canada cut their target price on Hologic from $75.00 to $70.00 and set a “sector perform” rating on the stock in a research report on Friday, May 2nd. Evercore ISI boosted their price objective on shares of Hologic from $62.00 to $68.00 and gave the company an “in-line” rating in a research report on Tuesday, July 8th. Mizuho increased their target price on shares of Hologic from $65.00 to $70.00 and gave the company an “outperform” rating in a research note on Wednesday. Stephens lowered their target price on shares of Hologic from $77.00 to $70.00 and set an “overweight” rating for the company in a report on Tuesday, May 13th. Finally, Wall Street Zen downgraded shares of Hologic from a “buy” rating to a “hold” rating in a report on Monday, May 5th. Eleven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Hologic has an average rating of “Hold” and a consensus price target of $77.33.

Insider Transactions at Hologic

In other Hologic news, Director Martin D. Madaus purchased 5,445 shares of Hologic stock in a transaction dated Wednesday, May 7th. The stock was acquired at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the acquisition, the director owned 5,445 shares in the company, valued at $300,781.80. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.88% of the stock is currently owned by insiders.

Hologic Stock Down 0.0%

Shares of NASDAQ HOLX opened at $63.99 on Friday. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.67. The firm has a market capitalization of $14.26 billion, a price-to-earnings ratio of 27.00, a PEG ratio of 2.35 and a beta of 0.55. The stock has a 50 day moving average price of $62.46 and a 200 day moving average price of $63.25. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.52 and a current ratio of 3.24.

Hologic (NASDAQ:HOLX) last issued its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. During the same period in the prior year, the business earned $1.03 EPS. The business’s revenue for the quarter was down 1.2% compared to the same quarter last year. Sell-side analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.